Summary
Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.
History
Organicell Regenerative Medicine was founded in 2006 with a simple mission: to advance regenerative medicine technology and shape the future of tissue engineering science. The Company has developed a proprietary technology platform that makes it easy to create and replicate cell cultures that can be used in regenerative medicine research. Since then, Organicell Regenerative Medicine has been working to advance the regenerative field by developing innovative products, tools and services that accelerate the progress of regenerative sciences.
Mission
Organicell Regenerative Medicine is dedicated to developing and utilizing cutting-edge tools and technologies to advance the cause of regenerative medicine, bringing the benefits of this exciting field of medicine to a global audience.
Vision
Organicell Regenerative Medicine seeks to revolutionize tissue engineering and regenerative medicine, providing an easy-to-use platform that boosts productivity and reduces complexity. Our goal is to create an accessible, interoperable and sustainable platform, revolutionizing the way research is conducted.
Key Team
Dr. George C. Shapiro FACC, M.D. (Chief Medical Officer & Director)
Mr. David Aciego (Chief Information Officer)
Recognition and Awards
Organicell Regenerative Medicine has been recognized for its contributions to the advancement of regenerative medicine, receiving multiple awards, including 'Innovator of the Year' from Frost & Sullivan in 2009 and the 'Breakthrough Research Award' from the International Regenerative Medicine Society in 2011.
References
